Diagnostic features, treatment, and survival in 258 pediatric patients with −7 or del(7q) ± other chromosomal aberrations
| Feature . | Cytogenetic subgroup . | |||
|---|---|---|---|---|
| −7 . | −7 other . | del(7q) . | del(7q) other . | |
| No. of patients | 90 | 82 | 21 | 65 |
| Year of diagnosis, no. | ||||
| 1985-1990 | 14 | 13 | 5 | 17 |
| 1991-1996 | 36 | 31 | 7 | 23 |
| 1997-2002 | 40 | 38 | 9 | 25 |
| Male sex, no. (%) | 57 (63) | 39 (48) | 10 (48) | 39 (60) |
| Median age, y | 7.2 | 8.8 | 7.6 | 8.5 |
| Younger than 6 y, no. | 39 | 26 | 6 | 28 |
| 6-11 y, no. | 27 | 35 | 10 | 21 |
| At least 12 y, no. | 24 | 21 | 5 | 16 |
| Median WBC count, × 109/L* | 10.9 | 15.0 | 13.2 | 13.7 |
| Less than 20 × 109/L | 57 | 42 | 10 | 38 |
| At least 20 × 109/L | 28 | 29 | 8 | 22 |
| Median PB blasts, %† | 13 | 20 | 41 | 39 |
| Median BM blasts, %†‡ | 39 | 57 | 71 | 68 |
| FAB classification, no. | ||||
| RAEB-T | 15 | 9 | 0 | 0 |
| AML-M0 | 10 | 6 | 3 | 3 |
| AML-M1 | 12 | 11 | 7 | 7 |
| AML-M2 | 23 | 18 | 6 | 19 |
| AML-M3 | 0 | 0 | 0 | 2 |
| AML-M4 | 12 | 16 | 2 | 15 |
| AML-M5 | 7 | 5 | 3 | 7 |
| AML-M6 | 5 | 4 | 0 | 3 |
| AML-M7 | 4 | 8 | ;0 | 6 |
| AML-unspecified | 2 | 5 | 0 | 3 |
| Hepatomegaly, no. (%)§ | 42 (50) | 36 (53) | 4 (22) | 24 (41) |
| Splenomegaly, no. (%)‡ | 41 (48) | 27 (40) | 7 (40) | 22 (37) |
| Treatment, no. (%) | ||||
| AML therapy | 87 (97) | 81 (99) | 21 (100) | 63 (97) |
| CR obtained | 55 (61) | 47 (58) | 18 (86) | 57 (90) |
| HSC transplantation | 39 (43) | 33 (40) | 9 (43) | 16 (25) |
| Survival, %; | ||||
| 5-y OS | 35 | 25 | 43 | 54 |
| 5-y EFS | 28 | 17 | 39 | 47 |
| Feature . | Cytogenetic subgroup . | |||
|---|---|---|---|---|
| −7 . | −7 other . | del(7q) . | del(7q) other . | |
| No. of patients | 90 | 82 | 21 | 65 |
| Year of diagnosis, no. | ||||
| 1985-1990 | 14 | 13 | 5 | 17 |
| 1991-1996 | 36 | 31 | 7 | 23 |
| 1997-2002 | 40 | 38 | 9 | 25 |
| Male sex, no. (%) | 57 (63) | 39 (48) | 10 (48) | 39 (60) |
| Median age, y | 7.2 | 8.8 | 7.6 | 8.5 |
| Younger than 6 y, no. | 39 | 26 | 6 | 28 |
| 6-11 y, no. | 27 | 35 | 10 | 21 |
| At least 12 y, no. | 24 | 21 | 5 | 16 |
| Median WBC count, × 109/L* | 10.9 | 15.0 | 13.2 | 13.7 |
| Less than 20 × 109/L | 57 | 42 | 10 | 38 |
| At least 20 × 109/L | 28 | 29 | 8 | 22 |
| Median PB blasts, %† | 13 | 20 | 41 | 39 |
| Median BM blasts, %†‡ | 39 | 57 | 71 | 68 |
| FAB classification, no. | ||||
| RAEB-T | 15 | 9 | 0 | 0 |
| AML-M0 | 10 | 6 | 3 | 3 |
| AML-M1 | 12 | 11 | 7 | 7 |
| AML-M2 | 23 | 18 | 6 | 19 |
| AML-M3 | 0 | 0 | 0 | 2 |
| AML-M4 | 12 | 16 | 2 | 15 |
| AML-M5 | 7 | 5 | 3 | 7 |
| AML-M6 | 5 | 4 | 0 | 3 |
| AML-M7 | 4 | 8 | ;0 | 6 |
| AML-unspecified | 2 | 5 | 0 | 3 |
| Hepatomegaly, no. (%)§ | 42 (50) | 36 (53) | 4 (22) | 24 (41) |
| Splenomegaly, no. (%)‡ | 41 (48) | 27 (40) | 7 (40) | 22 (37) |
| Treatment, no. (%) | ||||
| AML therapy | 87 (97) | 81 (99) | 21 (100) | 63 (97) |
| CR obtained | 55 (61) | 47 (58) | 18 (86) | 57 (90) |
| HSC transplantation | 39 (43) | 33 (40) | 9 (43) | 16 (25) |
| Survival, %; | ||||
| 5-y OS | 35 | 25 | 43 | 54 |
| 5-y EFS | 28 | 17 | 39 | 47 |
WBC indicates white blood cell.
*n = 234.
†n = 224.
‡n = 230.
§n = 229.